bioRxivCancer Biology
Mutant KRAS-associated proteome is mainly controlled by exogenous factors
P. Dias Carvalho, F. Martins, J. Carvalho, M. J. Oliveira, S. Velho
Abstract
KRAS signaling has been extensively studied, yet the clarification between KRAS-autonomous and non-autonomous mechanisms are still less explored. Understanding how KRAS signaling and effects are affected by exogenous stimuli can provide valuable insights not only to understand resistance mechanisms that justify pathway inhibition failure, but also to uncover novel therapeutic targets for mutant KRAS patients. Hence, aiming at understanding KRAS-autonomous versus non autonomous mechanisms, we studied the response of two mutant KRAS colorectal cancer cell lines (HCT116 and LS174T) - control and KRAS silenced- to TGF{beta}1-activated fibroblasts secretome. By performing a total proteome analysis, we observed that TGF{beta}1-activated fibroblast-secreted factors triggered cell line-specific proteome alterations and that mutant KRAS governs approximately 1/3 of those alterations. Moreover, the analysis of the impact of exogenous factors on the modulation of KRAS proteome revealed that, in both cell lines, more than 2/3 of the KRAS-associated proteome is controlled in a KRAS-non-autonomous manner and dependent on the exogenous factors. This work highlights the context-dependency of KRAS-associated signaling and reinforces the importance of establishing more integrative models resembling the complexity of the tumor microenvironment to study KRAS-associated signals.
- organism: human
- assay: proteomics
- research focus: cell signaling & trafficking
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: cell-cell communication
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Modulation of fibroblasts phenotype by colorectal cancer cells-secreted factors is mostly independent of oncogenic KRAS
P. Dias Carvalho, S. Mendonca, … S. Velho·CellsPeer-reviewed·Aug 11, 2022
- Unveiling the Mechanisms to Bypass KRAS Inhibition: In Vitro Insights into the Influence of Fibroblast-Secretome
Susana Mendonça, Patrícia Dias Carvalho, … Sérgia Velho·CancersPeer-reviewed·Jul 20, 2024
- Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis
P. Dias-Carvalho, F. Martins, … S. Velho·bioRxiv·Nov 16, 2021
- Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming.
A. Velez-Delgado, K. L. Donahue, … M. Pasca di Magliano·bioRxiv·Aug 26, 2021
- Targeted phosphoproteomics of the Ras signaling network reveal regulatory mechanisms mediated by oncogenic KRAS
A. Urisman, T. L. Yuan, … F. McCormick·bioRxiv·Jul 9, 2019
- Interplay Between KRAS and LZTR1 Protein Turnover, Controlled by CUL3/LZTR1 E3 Ubiquitin Ligase, is Disrupted by KRAS Mutations
Andreas Damianou, Zhu Liang, … Benedikt Mathias Kessler·bioRxiv·Nov 23, 2021